Plasma fibroblast activation protein is decreased in acute heart failure despite cardiac tissue upregulation
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Genovés, P
Grupos
Abstract
Background Cardiac fibroblast activation protein (FAP) has an emerging role in heart failure (HF). A paradoxical reduction in its levels in pathological conditions associated with acute processes has been observed. We aimed to identify FAP cardiac tissue expression and its relationship with the main cardiac fibrosis-related signaling pathways, and to compare plasma FAP levels in acute and chronic HF patients. Methods Transcriptomic changes were assessed via mRNA/ncRNA-seq in left ventricle tissue from HF patients (n = 57) and controls (n = 10). Western blotting and immunohistochemistry were used to explore FAP protein levels and localization in cardiac tissue. ELISA was performed to examine plasma FAP levels in acute HF (n = 48), chronic HF (n = 15) and control samples (n = 7). Results FAP overexpression in cardiac tissue is related to the expression of molecules directly involved in cardiac fibrosis, such as POSTN, THBS4, MFAP5, COL1A2 and COL3A1 (P < 0.001), and is directly and inversely related to pro- and antifibrotic microRNAs, respectively. The observed FAP overexpression is not reflected in plasma. Circulating FAP levels were lower in acute HF patients than in controls (P < 0.05), while chronic HF patients did not show significant changes. The clinical variables analyzed, such as functional class or etiology, do not affect plasma FAP concentrations. Conclusions We determined that in HF cardiac tissue, FAP is related to the main cardiac fibrosis signaling pathways as well as to pro- and antifibrotic microRNAs. Additionally, an acute phase of HF decreases plasma FAP levels despite the upregulation observed in cardiac tissue and regardless of other clinical conditions.
Datos de la publicación
- ISSN/ISSNe:
- 1479-5876, 1479-5876
- Tipo:
- Article
- Páginas:
- -
- PubMed:
- 38297310
- Factor de Impacto:
- 1,570 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
Journal of Translational Medicine BMC
Citas Recibidas en Web of Science: 10
Documentos
- No hay documentos
Filiaciones
Keywords
- Heart failure; FAP; Cardiac fibroblasts; Fibrosis; microRNAs; Acute heart failure
Proyectos y Estudios Clínicos
Identification of small non-coding rnas and their pathophysiological implication in heart failure. cardiac-related candidate selection in liquid biopsy for its functional characterization.
Investigador Principal: ESTEFANÍA TARAZÓN MELGUIZO
PI20/00071 . INSTITUTO DE SALUD CARLOS III . 2021
Contratos Miguel Servet 2021. Estefanía Tarazón.
Investigador Principal: ESTEFANÍA TARAZÓN MELGUIZO
CP21/00041 . INSTITUTO DE SALUD CARLOS III . 2022
Contrato PFIS 2021. Isaac Giménez
Investigador Principal: ESTEFANÍA TARAZÓN MELGUIZO
FI21/00034 . INSTITUTO DE SALUD CARLOS III . 2022
Contrato PFIS 2021. Lorena Pérez
Investigador Principal: ESTHER ROSELLÓ LLETÍ
FI21/00186 . INSTITUTO DE SALUD CARLOS III . 2022
Desarrollo de un sistema no invasivo de diagnóstico de rechazo cardíaco y de pronóstico.
Investigador Principal: ESTHER ROSELLÓ LLETÍ
CNS2022-135769 . MINISTERIO DE CIENCIA E INNOVACION . 2023
Identificacion de RNAs pequenos no codificantes en suero y su papel en la fisiopatologia de la insuficiencia cardiaca avanzada. Utilidad en la monitorizacion no invasiva de los pacientes tras el trasplante cardiaco
Investigador Principal: ESTHER ROSELLÓ LLETÍ
CIACIF/2022/429 . CONSELLERIA DE INNOVACIÓN, UNIVERSIDADES, CIENCIA Y SOCIEDAD DIGITAL . 2023
Cita
DELGADO M,Genovés P,PÉREZ L,GONZÁLEZ I,GIMÉNEZ I,MARTÍNEZ L,PORTOLÉS M,TARAZÓN E,ROSELLÓ E. Plasma fibroblast activation protein is decreased in acute heart failure despite cardiac tissue upregulation. J. Transl. Med. 2024. 22. (1):124. IF:7,500. (1).
Portal de investigación